NCT06799533View on ClinicalTrials.gov

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Malignant MelanomaMelanomaMetastatic MelanomaSolid Tumors
Interventions
DRUG

PF-08046031

Given into the vein (IV; intravenous)

Trial Locations (10)

80218

Sarah Cannon Research Institute at HealthONE - SCRI - PPDS, Denver

90025

The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles

The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate, Los Angeles

90404

The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only), Santa Monica

94143

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94158

UCSF Medical Center, Investigational Pharmacy, San Francisco

94800

Gustave Roussy, Villejuif

08035

Hospital Universitari Vall d'Hebron, Barcelona

171 64

Karolinska Universitetssjukhuset Solna, Solna

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06799533 - A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | Biotech Hunter | Biotech Hunter